PALM BEACH, Florida, May 28, 2020 /PRNewswire/ -- Glioblastoma is a type of brain cancer. It's the most common type of malignant brain tumor among adults. And it is usually very aggressive, which means it can grow fast and spread quickly. Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders. Although there is no cure, there are treatments to help ease symptoms. Active biotech companies with recent developments include: Nascent Biotech, Inc. (OTCQB: NBIO), Mersana Therapeutics, Inc. (NASDAQ: MRSN), Agenus Inc. (NASDAQ: AGEN), GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc. (NYSE: PFE).
Presently, the goal of glioblastoma treatment is to slow and control tumor growth and help you live as comfortably and as well as possible. In many cases, surgery is recommended in combination with one or more other treatment techniques. The best possible treatment for you will depend on many factors that are unique to you, which is why it is important that you receive a treatment plan that's tailored to your individual needs. Researchers are continually working to improve the glioblastoma survival rate. Patients have a wider range of treatment options than ever before, and new therapies are being introduced on a regular basis. Additionally, clinical studies are providing better insight into how different cancers and cell types respond to treatment, allowing oncologists to recommend more effective therapies for each patient. For instance, researchers have identified a specific protein that makes glioblastomas less responsive to a commonly prescribed chemotherapy drug; oncologists can test patients for this protein to determine if a different medication might be more effective before treatment even begins.
Nascent Biotech, Inc. (OTCQB: NBIO) BREAKING NEWS: Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug - Nascent Biotech (the "Company" or "Nascent") pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer.
The study will employ Nascent's monoclonal, antibody, Pritumumab ("PTB") and will be conducted in collaboration with a Southern CA Cancer Center as noted in their release which can be viewed at https://www.nascentbiotech.com/hoag-is-first-in-nation-to-test-innovative-antibody-brain-cancer-drug/
Nascent's lead therapeutic asset, PTB, is a natural human antibody that works by binding to ectodomain vimentin (EDV), a protein expressed on the surface of epithelial cancers. The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.
Because EDV is found in a variety of cancers, these important clinical trials of PTB could have implications for a broad range of more common cancers, such as breast, colon and lung. The current Phase 1 trials have been uniquely designed to ultimately treat a variety of brain cancers from gliomas and other primary brain tumors to brain metastases and leptomeningeal cancers arising from breast, lung and other solid tumors.
Sean Carrick, CEO of Nascent Biotech, states, "Nascent is committed to opening this trial and delivering this promising treatment to patients afflicted with this devastating disease." Read this entire press release and more news for NBIO at: https://www.financialnewsmedia.com/news-nbio
Other industry developments from around the markets include:
Mersana Therapeutics, Inc. (NASDAQ: MRSN) recently reported interim safety, tolerability and efficacy data from the ongoing expansion portion of the Phase 1 study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung (NSCLC) adenocarcinoma. The Company will host a conference call and webcast today, Wednesday, May 27, 2020, at 8:00 a.m. ET during which investigator Debra L. Richardson, MD, Associate Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute and members of the Mersana executive team will present and discuss these data. These data will also be presented in a poster session at the American Society of Clinical Oncology 2020 Virtual Scientific Program on Friday, May 29, 2020 starting at 8:00 a.m. ET.
"These data demonstrate not only that XMT-1536, our first-in-class Dolaflexin ADC targeting NaPi2b, can deliver confirmed complete responses, partial responses and durable stable disease in platinum-resistant ovarian cancer, but also that these responses can deepen over time in a patient population with poor prognosis and limited treatment options," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "XMT-1536 continues to demonstrate that it is generally well tolerated, without the dose-limiting toxicities of other ADC platforms such as severe neutropenia, neuropathy and ocular toxicity. These are encouraging signals as we look forward to reporting more mature data in the second half of the year and continuing to advance XMT-1536 for both platinum-resistant ovarian cancer and NSCLC adenocarcinoma patients."
Agenus Inc. (NASDAQ: AGEN) an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infections, announced that it will present data on AGEN1181 at the American Society of Clinical Oncology (ASCO) upcoming ASCO2020 Virtual Scientific Program to be held May 29-31, 2020.
AGEN1181 is a multifunctional Fc-engineered next generation anti-CTLA-4 antibody which has been designed to improve upon the safety and efficacy shown with first-generation CTLA-4 antibodies.
The virtual presentation will be made by Dr. Steven J. O'Day, the Executive Director of the John Wayne Cancer Institute and Cancer Clinic, and Director of Providence Los Angeles Regional Research.
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA.
Under the terms of the agreement, Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing. This capacity will be flexible depending on GSK's future needs and will supplement GSK's existing manufacturing network.
Regis Simard, President, Pharmaceuticals Supply Chain, GSK, said, "Today's agreement with Samsung Biologics complements and reinforces our existing world-class pharmaceutical manufacturing capability and will help ensure we can continue to deliver the transformative medicines that patients need."
"We are very proud and excited to announce this long-term agreement with GSK," said Dr. Tae Han Kim, CEO of Samsung Biologics. "Samsung Biologics entered the biopharma industry with the goal to help our clients bring valuable biological medicines to patients faster. We are thrilled to partner with GSK, a company who shares the vision."
Pfizer Inc. (NYSE: PFE) recently announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary data from 9 ambulatory boys with DMD, aged 6 to 12 (mean age: 8 years) indicate that the intravenous administration of PF-06939926 was well-tolerated during the infusion period, with encouraging efficacy and manageable safety events, even when considering those adverse events that were more severe in nature. The treatment provided durable and statistically significant improvements across multiple efficacy-related endpoints measured at 12 months post-infusion, including sustained levels of mini-dystrophin expression and improvements on the North Star Ambulatory Assessment (NSAA) rating scale, which is a validated measure of muscle function. Three serious adverse events (SAEs) were recorded, two of which reflected likely complement activation. While these two SAEs were severe in nature, all three events fully resolved within 2 weeks, providing encouragement that close monitoring and early intervention can help mitigate the effects of complement activation. This new dataset, which includes updated 12-month results on safety, dystrophin expression, and exploratory functional endpoints for 3 additional boys, was presented for the first time during a virtual oral session today at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated forty six hundred dollars for coverage of news issued by Nascent Biotech, Inc. by a non-affiliated third party.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
email: [email protected]